Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates

分组1 - Alkermes reported quarterly earnings of $0.52 per share, exceeding the Zacks Consensus Estimate of $0.41 per share, but down from $0.72 per share a year ago, representing an earnings surprise of +26.83% [1] - The company posted revenues of $390.66 million for the quarter, surpassing the Zacks Consensus Estimate by 15.38%, although this is a decrease from year-ago revenues of $399.13 million [2] - Over the last four quarters, Alkermes has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] 分组2 - The stock has underperformed the market, losing about 9.1% since the beginning of the year compared to the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the coming quarter is $0.48 on revenues of $353.2 million, and for the current fiscal year, it is $1.81 on revenues of $1.37 billion [7] - The Medical - Biomedical and Genetics industry, to which Alkermes belongs, is currently in the top 38% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]